IDH-specific vaccine for high-grade gliomas

IDH-specific vaccine for high-grade gliomas

VJOncology

1 year
494 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The NOA-16 trial is a multicenter, Phase I trial, which enrolled patients with newly diagnosed grade III and IV astrocytomas with specific IDH mutations. Here, Wolfgang Wick, MD, of the German Cancer Research Center, Heidelberg, Germany, speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, provides an overview of this trial, explaining how the IDH-specific vaccine tested will be integrated into the first-line treatment of these patients. The immunogenicity of the vaccine in the blood and tumors of the patients after treatment was assessed, and further investigations will now be carried out to detect the specific immune responses occuring when this treatment is combined with the immune checkpoint inhibitor avelumab.
Up Next Autoplay
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Category: Brain Cancer
5 Views
Cancer-News 6 days
Mount Sinai Receives More Than $10 Million in Grant Funding for Brain Tumor Research
Mount Sinai Receives More Than $10 Million in Grant Funding for Brain Tumor Research
Category: Brain Cancer
6 Views
Cancer-News 2 weeks
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Category: Brain Cancer
15 Views
alexvarney 2 months
Predicting Tumor Recurrence: How Does This Help Us?
Predicting Tumor Recurrence: How Does This Help Us?
Category: Brain Cancer
9 Views
Baylor College of Medicine 3 months
Predicting Tumor Recurrence
Predicting Tumor Recurrence
Category: Brain Cancer
20 Views
Baylor College of Medicine 3 months
How does this affect clinicians today?
How does this affect clinicians today?
Category: Brain Cancer
10 Views
Cleveland Clinic 4 months
Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells
Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells
Category: Brain Cancer
25 Views
Cleveland Clinic 4 months
Oncoceutics Commemorates National Childhood Cancer Awareness Month
Oncoceutics Commemorates National Childhood Cancer Awareness Month
Category: Brain Cancer
19 Views
alexvarney 4 months
Publication Reports Clinical Efficacy of ONC201 in Expanded Access H3 K27M-mutant Glioma Patients
Publication Reports Clinical Efficacy of ONC201 in Expanded Access H3 K27M-mutant Glioma Patients
Category: Brain Cancer
38 Views
alexvarney 4 months
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206
Category: Brain Cancer
42 Views
alexvarney 4 months